In a phase III trial, the combination of nivolumab and ipilimumab yielded more and longer responses than sunitinib in patients with renal cell carcinoma at intermediate or high risk of progression. More than 41% of patients who received the immunotherapy combination responded, compared with 26. 5% of patients who received sunitinib. Patients receiving the combination also experienced longer progression-free survival and fewer side effects.
Cancer discovery. 2017 Sep 25 [Epub ahead of print]